Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alex John Liu"'
Autor:
Alex John Liu, Daniel Walden, Syeda Mina, Blake Langlais, Leylah Drusbosky, Dong Yang, Jason S. Starr, Jeremy Clifton Jones, Tanios S. Bekaii-Saab, Daniel H. Ahn, Mohamad B. Sonbol
Publikováno v:
Journal of Clinical Oncology. 40:3590-3590
3590 Background: Co-occurring alterations (COAs) in the HER2 and MAPK pathway are rare in mCRC. RAS, HER2 and BRAF alterations have been associated with resistance to EGFR inhibitor therapy (EGFR-mab). Typical co-occurring mutually exclusive gene mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7603faa1f9823349288f209316a1a4d0
https://doi.org/10.1200/jco.2022.40.16_suppl.3590
https://doi.org/10.1200/jco.2022.40.16_suppl.3590
Autor:
Patrick Walsh McGarrah, Jennifer Gile, Alex John Liu, Aaron Scott Mansfield, Konstantinos Leventakos, Aakash Desai, Sri Harsha Tella, Bassam Bassam Sonbol, Jason S. Starr, Timothy J. Hobday, Thorvardur Ragnar Halfdanarson
Publikováno v:
Journal of Clinical Oncology. 40:512-512
512 Background: The role of immune checkpoint inhibitors (ICIs) in the treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC) has yet to be established. While objective responses have been observed, it is still unknown which patients are likel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0fd7269174a2f33fd889bb3758734a9b
https://doi.org/10.1200/jco.2022.40.4_suppl.512
https://doi.org/10.1200/jco.2022.40.4_suppl.512
Autor:
Daniel Walden, Fang-Shu Ou, Joseph J. Larson, Christina Wu, Sandra Kang, Alex John Liu, Cassia R Griswold, Benjamin Edward Ueberroth, Bhamini Patel, Amber Draper, Kelley Rone, Puneet Raman, Tanios S. Bekaii-Saab, Daniel H. Ahn
Publikováno v:
Journal of Clinical Oncology. 40:92-92
92 Background: Since the publication of the MOSAIC trial, stage III CC has been treated with a six-month (mo) regimen of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine and oxaliplatin). Recently, the IDEA collaboration chal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9464e69db7d5e259b691c27e42338bee
https://doi.org/10.1200/jco.2022.40.4_suppl.092
https://doi.org/10.1200/jco.2022.40.4_suppl.092
Autor:
Lionel Aurelien Kankeu Fonkoua, Sakti Chakrabarti, Mohamad Bassam Sonbol, Pashtoon Murtaza Kasi, Jason Scott Starr, Alex John Liu, Melanie C. Bois, Henry C. Pitot, Chandrikha Chandrasekharan, Helen J. Ross, Tsung-Teh Wu, Rondell P. Graham, Svetomir Markovic, Haidong Dong, Harry H. Yoon
Publikováno v:
Journal of Clinical Oncology. 38:4541-4541
4541 Background: Anti-VEGFR2 therapy (ramucirumab/paclitaxel [RAM/TAX]) and ICI are approved as 2nd- and 3rd-line therapy (Tx), respectively, for pts with mGEA. We unexpectedly saw durable responses in 2 pts on RAM/TAX after progression on an ICI tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d63c495cbe7830216256e9b07a0e00e9
https://doi.org/10.1200/jco.2020.38.15_suppl.4541
https://doi.org/10.1200/jco.2020.38.15_suppl.4541